Amneal Pharmaceuticals (AMRX) Receivables - Other: 2017-2025
Historic Receivables - Other for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to $24.2 million.
- Amneal Pharmaceuticals' Receivables - Other rose 208.08% to $24.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.2 million, marking a year-over-year increase of 208.08%. This contributed to the annual value of $9.1 million for FY2024, which is 7.93% down from last year.
- Per Amneal Pharmaceuticals' latest filing, its Receivables - Other stood at $24.2 million for Q3 2025, which was up 48.22% from $16.3 million recorded in Q2 2025.
- Over the past 5 years, Amneal Pharmaceuticals' Receivables - Other peaked at $100.0 million during Q2 2022, and registered a low of $1.1 million during Q1 2021.
- Over the past 3 years, Amneal Pharmaceuticals' median Receivables - Other value was $14.0 million (recorded in 2023), while the average stood at $13.8 million.
- In the last 5 years, Amneal Pharmaceuticals' Receivables - Other plummeted by 93.27% in 2021 and then surged by 4,184.30% in 2022.
- Amneal Pharmaceuticals' Receivables - Other (Quarterly) stood at $9.8 million in 2021, then soared by 239.13% to $33.1 million in 2022, then tumbled by 70.03% to $9.9 million in 2023, then decreased by 7.93% to $9.1 million in 2024, then spiked by 208.08% to $24.2 million in 2025.
- Its Receivables - Other stands at $24.2 million for Q3 2025, versus $16.3 million for Q2 2025 and $20.5 million for Q1 2025.